Azilsartan Medoxomil

Indications

Azilsartan Medoxomil is used for: Hypertension, alone or in combination w/ other antihypertensive agents.

Adult Dose

Adult: Initially 40 mg once daily. May be increased to a max of 80 mg once daily as necessary. Elderly: No dose adjustment is necessary in elderly patients

Child Dose

Renal Dose

Renal Impairment No dose adjustment is required with mild-to-severe renal impairment or end-stage renal disease. Patients with moderate-to-severe renal impairment are more likely to report high serum creatinine values.

Administration

May be taken with or without food.

Contra Indications

Hypersensitivity. Pregnancy.

Precautions

Correct vol or salt depletion prior to administration. Renal (moderate to severe) & hepatic (severe) impairment. Pregnancy (1st trimester) & lactation. Childn <18 yr. Monitor serum K in patients taking K-sparing diuretics, salt substitutes containing K & drugs that increase K levels (eg heparin) & creatinine levels in patients w/ renal impairment & type 2 DM. Aortic or mitral valve stenosis, hypertrophic obstructive cardiomyopathy. Lactation: unknown whether distributed in breast milk, decide on alternate antihypertensive therapy or do not breastfeed

Pregnancy-Lactation

Pregnancy Category: C (1st trimester); D (2nd and 3rd trimesters)

Interactions

Reversibly increases serum conc & toxicity of lithium; attenuated antihypertensive effects & risk of worsening of renal function may occur w/ NSAIDs. Hyperkalemia w/ K-sparing diuretics & K supplements.

Adverse Effects

Side effects of Azilsartan Medoxomil : 1-10% Diarrhea (2%) <1% Nausea, Asthenia, Fatigue, Muscle spasm, Dizziness, Postural hypotension, Cough

Mechanism of Action

Angiotensin II blocker; displaces angiotensin II from AT1 receptor and may lower blood pressure by antagonizing AT1-induced vasoconstriction, aldosterone release, catecholamine release, arginine vasopressin release, water absorption, and hypertrophic responses. May induce more complete inhibition of renin-angiotensin system compared with ACE inhibitors; does not affect response to bradykinin. Inhibits the pressor effects of an angiotensin II infusion in a dose-related manner.